Drugs / QM1114-DP
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 35 trials · 2 met primary | ||||||
| Phase 3 | NCT05148000 | Jan → Mar 2023 | eyelid disorder | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT05463965 | Jul 2022 → Jan 2023 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04249583 | Feb → Aug 2020 | — | Galderma R&D | Completed | No outcome recorded |
| Phase 3 | NCT04247074 | Feb → Oct 2020 | disease of orbital part of eye adnexa | Galderma R&D | Completed | Met primary |
| Phase 3 | NCT04225260 | Jan 2020 → Apr 2021 | eyelid disorder | Galderma R&D | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05146999 Comparator | May → Oct 2022 | — | Galderma R&D | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QM1114-DP | “The investigational product (QM1114-DP) is a BoNT Type A.” NCT04225260 ↗5“QM1114-DP, a Botulinum Toxin Type A (BoNT-A)” NCT04249583 ↗ “QM1114-DP, a Botulinum Toxin Type A (BoNT-A)” NCT04247074 ↗ |
| Modality | Protein / enzyme biologic | “The investigational product (QM1114-DP) is a BoNT Type A.” NCT04225260 ↗ |
| Route | Other | “A dose of QM1114-DP will be injected in the GL area and in the LCL area.” NCT04225260 ↗ |